VivoSeq
Other

HER2-Negative

4

Pipeline Programs↗

4

Active Trials↗

6

Companies Involved↗

HER2-Negative is an early-stage landscape with 4 programs across 6 companies. The most active players are Gilead, Bristol-Myers Squibb, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

33/100

Attrition Rate

29/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Gilead logo

Gilead

1 program

Phase 2Bristol-Myers Squibb logo

Bristol-Myers Squibb

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2Teva logo

Teva

1 program

Phase 2O

Odonate Therapeutics, Inc.

0 programs

PreclinicalPfizer logo

Pfizer

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical
No programs
Phase 1
No programs
Phase 24

Denikitug

Gilead

Nivolumab

Bristol-Myers Squibb

Ramucirumab

Eli Lilly

Paclitaxel

Teva

Phase 3
No programs
Approved
No programs

Analysis

Modality Breakdown

4programs
Small molecule250%
Monoclonal antibody250%

Modality classified for 100% of 4 pipeline programs.

Analysis

Trial Status

7

clinical trials

Recruiting3 · 43%
Terminated2 · 29%
Not yet recruiting1 · 14%
Completed1 · 14%

Clinical Trials

Trial Activity

7 trials

Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
Recruiting·FFirst Affiliated Hospital of Zhejiang University·Phase 2·NCT06705127·30 enrolled
A PoC Study to Evaluate Treatments' Efficacy by Monitoring MRD Using ctDNA in HR-positive/HER2-negative EBC Population
Recruiting·MMedSIR·Phase 2·NCT05708235·976 enrolled
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
Recruiting·Gilead logoGilead·Phase 2·NCT07546812·120 enrolled
To Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of HRS-6209 in Subjects With HR-Positive/HER2-Negative Solid Tumor
Not yet recruiting·AAtridia Pty Ltd.·Phase 1·NCT07358377·15 enrolled
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2m
Completed·Pfizer logoPfizer·N/A·NCT05141708·33 enrolled
Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Triple-Negative MBC and Tesetaxel Monotherapy in Patients With HER2-Negative MBC
Terminated·OOdonate Therapeutics, Inc.·Phase 2·NCT03952325·294 enrolled
Targeting the PAM50 Her2-Enriched Phenotype With Enzalutamide in Hormone Receptor-Positive/Her2-Negative Metastatic BC
Terminated·SSOLTI Breast Cancer Research Group·Phase 2·NCT04142060·34 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)